πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642384

Compositions and methods for the treatment of Netherton Syndrome

Krystal Biotech, Inc. Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11638704

Bicyclic compounds and their use in the treatment of cancer

TEMPEST THERAPEUTICS, INC. Β· Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11638708

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633377

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11634691

Compositions and methods of treatment

The Regents of the University of California Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633385

Combination compositions for treatment of cancer

RedHill Biopharma Ltd. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633511

Production of immune-response-stimulating aerosols by non-thermal plasma treatment of airb

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11628146

Estrogen receptor ligand treatment for neurodegenerative diseases

The Regents of the University of California Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11622991

Protocol for treatment of lupus nephritis

AURINIA PHARMACEUTICALS INC. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11623010

Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition a

BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11623918

Compounds for the treatment of acute and chronic kidney disease

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613739

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) p

REGENXBIO INC. Β· Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11610666

Systems and methods of managing treatment of a chronic condition by symptom tracking

Corcept Therapeutics Incorporated Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608381

Methods of treatment using a leptin receptor agonist antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608354

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory diseas

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11607450

Smallpox vaccine for cancer treatment

Calidi Biotherapeutics, Inc. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11607464

Compositions and methods for the treatment and imaging of cancer

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11607408

Method of treatment of schizophrenia

VANDA PHARMACEUTICALS INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11602551

Use of inosine for the treatment of t-reg deficiency

The Board of Regents of the University of Texas System Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603412

Antibodies against CDCP1 for the treatment and detection of cancer

The Regents of the University of California Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597765

Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

VACCINEX, INC. Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597773

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596688

Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted